Brr2-IN-3

Brr2-IN-3 (Brr2 Inhibitor C9) is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).

BRD4-IN-11 is an orally active and selective inhibitor of BRD4 with an IC50 of 26.35 nM for BD1 and 72.81 nM for BD2. Its potency against BRD4 is approximately 3 to 18 times greater than against BRr2, BRD3, and BRDT. BRD4-IN-11 increases H2S release and inhibits the upregulation of fibrosis markers (α-SMA and fibronectin), c-Myc, and CDC25B. It also reduces apoptosis in LO2 hepatic cells. In liver and lung fibrosis models, BRD4-IN-11 significantly improves liver and lung function, making it suitable for research on liver and lung fibrosis.